secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2023-10-24T23:59:59+00:00
Accession:  0001104659-23-110945
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BrainStorm cuts 30% headcount, CMO departs, plans NurOwn Phase 3b trial
-----------------------------------------------------------------------

- Reduction in force of ~30% with estimated severance costs of $450k-$900k, substantially complete by end of 2023.
- Dr. Kirk Taylor steps down as EVP and Chief Medical Officer effective October 18, 2023, not due to any disagreement.
- Company plans double-blind, placebo-controlled Phase 3b U.S. trial for NurOwn in ALS with open-label extension.
- Total resource consumption to be reduced by ~50% to fund ALS development; exploring capital raising options.
- Positions critical to Phase 3b trial and regulatory submission retained; clean room operations streamlined.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465923110945/0001104659-23-110945-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465923110945/tm2328929d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-110945

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer